Data gathered: November 27
AI Stock Analysis - Annexon (ANNX)
Analysis generated June 19, 2024. Powered by Chat GPT.
Annexon Biosciences is a clinical-stage biopharmaceutical company that focuses on developing novel therapies for patients with autoimmune and neurodegenerative diseases. Their leading approach targets the classical complement pathway, aiming to halt or reverse diseases driven by aberrant activation of this immune system component. Despite promising research ambitions, the company is in its developmental phase, an aspect crucial to consider for potential investors.
Stock Alerts - Annexon (ANNX)
 |
Annexon | November 26 Price is up by 5.3% in the last 24h. |
|
Annexon | November 20 Price is down by -5.1% in the last 24h. |
|
Annexon | November 18 Price is down by -6.1% in the last 24h. |
|
Annexon | November 12 Price is down by -5% in the last 24h. |
Alternative Data for Annexon
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 40 | Sign up | Sign up | Sign up |
| Google Trends | 9 | Sign up | Sign up | Sign up |
| Patents | 14 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 859 | Sign up | Sign up | Sign up |
| Twitter Followers | 300 | Sign up | Sign up | Sign up |
| Twitter Mentions | 19 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 21 | Sign up | Sign up | Sign up |
| Linkedin Employees | 96 | Sign up | Sign up | Sign up |
About Annexon
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders.
| Price | $5.34 |
| Target Price | Sign up |
| Volume | 732,720 |
| Market Cap | $548M |
| Year Range | $4.33 - $7.81 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Mutual of America Capital Management LLC Buys 19,681 Shares of Annexon, Inc. (NASDAQ:ANNX)November 22 - ETF Daily News |
|
FY2027 Earnings Estimate for Annexon Issued By HC WainwrightNovember 19 - ETF Daily News |
|
Acasti Pharma (NASDAQ:ACST) vs. Annexon (NASDAQ:ANNX) Head-To-Head ReviewNovember 18 - ETF Daily News |
 |
Annexon (NASDAQ:ANNX) Earns “Buy” Rating from Needham & Company LLCNovember 18 - ETF Daily News |
 |
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.November 18 - Yahoo |
|
Annexon (NASDAQ:ANNX) Receives Buy Rating from HC WainwrightNovember 17 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 9.3M | -9.3M | -35M | 0 | -0.250 |
| Q2 '24 | 0 | 8.6M | -8.6M | -30M | -33M | -0.230 |
| Q1 '24 | 0 | 7.6M | -7.6M | -25M | -28M | -0.210 |
| Q4 '23 | 300,000 | 6.7M | -6.4M | -28M | -29M | -0.360 |
| Q3 '23 | 600,000 | 6.9M | -6.3M | -32M | -34M | -0.430 |
Insider Transactions View All
| Yednock Ted filed to sell 71,365 shares at $7.4. October 17 '24 |
| Carson William H. filed to buy 22,400 shares at $6. October 2 '24 |
| Yednock Ted filed to sell 4,500 shares at $6.2. September 16 '24 |
| Yednock Ted filed to sell 10,000 shares at $5.6. September 6 '24 |
Similar companies
Read more about Annexon (ANNX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Annexon?
The Market Cap of Annexon is $548M.
What is the current stock price of Annexon?
Currently, the price of one share of Annexon stock is $5.34.
How can I analyze the ANNX stock price chart for investment decisions?
The ANNX stock price chart above provides a comprehensive visual representation of Annexon's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Annexon shares. Our platform offers an up-to-date ANNX stock price chart, along with technical data analysis and alternative data insights.
Does ANNX offer dividends to its shareholders?
As of our latest update, Annexon (ANNX) does not offer dividends to its shareholders. Investors interested in Annexon should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Annexon?
Some of the similar stocks of Annexon are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.